{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:44:18Z","timestamp":1792550658522,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-11-1-0104"],"award-info":[{"award-number":["W81XWH-11-1-0104"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016042"],"award-info":[{"award-number":["P30CA016042"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10549-015-3282-x","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T10:23:41Z","timestamp":1423304621000},"page":"669-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response"],"prefix":"10.1007","volume":"149","author":[{"given":"Sara A.","family":"Hurvitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Kalous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Dering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Kolarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Linnartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,8]]},"reference":[{"issue":"6797","key":"3282_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752","journal-title":"Nature"},{"issue":"19","key":"3282_CR2","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869\u201310874. doi: 10.1073\/pnas.191367098","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3282_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501. doi: 10.1038\/nrc839","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"3282_CR4","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"M Laplante","year":"2009","unstructured":"Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(20):3589\u20133594. doi: 10.1242\/jcs.051011","journal-title":"J Cell Sci"},{"issue":"9","key":"3282_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrc1974","volume":"6","author":"DM Sabatini","year":"2006","unstructured":"Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9):729\u2013734. doi: 10.1038\/nrc1974","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3282_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335\u2013348. doi: 10.1038\/nrc1362","journal-title":"Nat Rev Cancer"},{"issue":"7092","key":"3282_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441","author":"RJ Shaw","year":"2006","unstructured":"Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424\u2013430. doi: 10.1038\/nature04869","journal-title":"Nature"},{"issue":"14","key":"3282_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14):1296\u20131302. doi: 10.1016\/j.cub.2004.06.054","journal-title":"Curr Biol"},{"issue":"11","key":"3282_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11):1122\u20131128. doi: 10.1038\/ncb1183","journal-title":"Nat Cell Biol"},{"issue":"3","key":"3282_CR10","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471\u2013484. doi: 10.1016\/j.cell.2006.01.016","journal-title":"Cell"},{"issue":"20","key":"3282_CR11","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1158\/1078-0432.CCR-04-0112","volume":"10","author":"X Zhou","year":"2004","unstructured":"Zhou X, Tan M, Hawthorne VS, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D (2004) Activation of the Akt\/mammalian target of rapamycin\/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10(20):6779\u20136788. doi: 10.1158\/1078-0432.CCR-04-0112","journal-title":"Clin Cancer Res"},{"issue":"13","key":"3282_CR12","first-page":"3605","volume":"60","author":"V Stambolic","year":"2000","unstructured":"Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten\u00a0\u00b1\u00a0mice. Cancer Res 60(13):3605\u20133611","journal-title":"Cancer Res"},{"issue":"12","key":"3282_CR13","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-06-1609","volume":"13","author":"G Perez-Tenorio","year":"2007","unstructured":"Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13(12):3577\u20133584. doi: 10.1158\/1078-0432.CCR-06-1609","journal-title":"Clin Cancer Res"},{"issue":"17","key":"3282_CR14","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1242\/dev.129.17.4159","volume":"129","author":"G Li","year":"2002","unstructured":"Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, Hennighausen L, Wu H (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129(17):4159\u20134170","journal-title":"Development"},{"issue":"28","key":"3282_CR15","doi-asserted-by":"publisher","first-page":"19018","DOI":"10.1074\/jbc.M109.018937","volume":"284","author":"B Schade","year":"2009","unstructured":"Schade B, Rao T, Dourdin N, Lesurf R, Hallett M, Cardiff RD, Muller WJ (2009) PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 284(28):19018\u201319026. doi: 10.1074\/jbc.M109.018937","journal-title":"J Biol Chem"},{"issue":"41","key":"3282_CR16","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497\u20135510. doi: 10.1038\/onc.2008.245","journal-title":"Oncogene"},{"issue":"8","key":"3282_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550\u2013562. doi: 10.1038\/nrc2664","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"3282_CR18","first-page":"5985","volume":"61","author":"M Sun","year":"2001","unstructured":"Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ (2001) Phosphatidylinositol-3-OH Kinase (PI3K)\/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61(16):5985\u20135991","journal-title":"Cancer Res"},{"issue":"4","key":"3282_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ijc.2910640412","volume":"64","author":"A Bellacosa","year":"1995","unstructured":"Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64(4):280\u2013285","journal-title":"Int J Cancer"},{"key":"3282_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-540-31209-3_7","volume":"172","author":"A Boulay","year":"2007","unstructured":"Boulay A, Lane HA (2007) The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res 172:99\u2013124","journal-title":"Recent Results Cancer Res"},{"issue":"10","key":"3282_CR21","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588\u20131595. doi: 10.1200\/JCO.2007.14.0988","journal-title":"J Clin Oncol"},{"issue":"10","key":"3282_CR22","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal SR, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603\u20131610. doi: 10.1200\/JCO.2007.14.5482","journal-title":"J Clin Oncol"},{"issue":"1","key":"3282_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O\u2019Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64(1):252\u2013261","journal-title":"Cancer Res"},{"issue":"6483","key":"3282_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/369756a0","volume":"369","author":"EJ Brown","year":"1994","unstructured":"Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369(6483):756\u2013758. doi: 10.1038\/369756a0","journal-title":"Nature"},{"issue":"1","key":"3282_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","volume":"78","author":"DM Sabatini","year":"1994","unstructured":"Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78(1):35\u201343","journal-title":"Cell"},{"issue":"6","key":"3282_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. doi: 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"34","key":"3282_CR27","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","volume":"28","author":"F Andre","year":"2010","unstructured":"Andre F, Campone M, O\u2019Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110\u20135115. doi: 10.1200\/JCO.2009.27.8549","journal-title":"J Clin Oncol"},{"issue":"2","key":"3282_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","volume":"125","author":"G Jerusalem","year":"2011","unstructured":"Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447\u2013455. doi: 10.1007\/s10549-010-1260-x","journal-title":"Breast Cancer Res Treat"},{"key":"3282_CR29","doi-asserted-by":"publisher","DOI":"10.32.232110.1200\/JCO.2010.32.2321","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ (2011) Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. doi: 10.32.232110.1200\/JCO.2010.32.2321","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"3282_CR30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/jco.2013.31.15_suppl.505","volume":"31","author":"R O\u2019Regan","year":"2013","unstructured":"O\u2019Regan R, Ozguroglu M, Andre F, Toi M, Heinrich G, Jerusalem M, Wilks S, Isaacs C, Xu B, Masuda N, Arena FP, Yardley DA, Yap YS, Mukhopadhyay P, Douma S, El-Hashimy M, Taran T, Sahmoud T, Lebwohl DE, Gianni L (2013) Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 31(15 suppl):505","journal-title":"J Clin Oncol"},{"issue":"6","key":"3282_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, O\u2019Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580\u2013591. doi: 10.1016\/S1470-2045(14)70138-X","journal-title":"Lancet Oncol"},{"issue":"14","key":"3282_CR32","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","volume":"13","author":"S Mabuchi","year":"2007","unstructured":"Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13(14):4261\u20134270. doi: 10.1158\/1078-0432.CCR-06-2770","journal-title":"Clin Cancer Res"},{"issue":"29","key":"3282_CR33","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1038\/onc.2011.42","volume":"30","author":"B Weigelt","year":"2011","unstructured":"Weigelt B, Warne PH, Downward J (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30(29):3222\u20133233. doi: 10.1038\/onc.2011.42onc201142","journal-title":"Oncogene"},{"issue":"19","key":"3282_CR34","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13(19):5883\u20135888","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"3282_CR35","first-page":"509","volume":"31","author":"HS Rugo","year":"2013","unstructured":"Rugo HS, Hortobagyi GN, Piccart-Gebhart MJ, Burris HA, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Provencher L, Masuda N, Dakhil SR, Anderson I, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J (2013) Correlation of molecular alterations with efficacy of everolimus in hormone-receptor\u2013positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31(suppl 15):509","journal-title":"J Clin Oncol"},{"issue":"6","key":"3282_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515\u2013527. doi: 10.1016\/j.ccr.2006.10.008","journal-title":"Cancer Cell"},{"issue":"3","key":"3282_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","volume":"105","author":"RS Finn","year":"2007","unstructured":"Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201dtriple-negative\u201d breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105(3):319\u2013326. doi: 10.1007\/s10549-006-9463-x","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"3282_CR38","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5):R77. doi: 10.1186\/bcr2419","journal-title":"Breast Cancer Res"},{"issue":"9","key":"3282_CR39","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/1535-7163.MCT-11-0730","volume":"11","author":"O Kalous","year":"2012","unstructured":"Kalous O, Conklin D, Desai AJ, O\u2019Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS (2012) Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther 11(9):1978\u20131987. doi: 10.1158\/1535-7163.MCT-11-0730","journal-title":"Mol Cancer Ther"},{"issue":"7391","key":"3282_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603\u2013607. doi: 10.1038\/nature11003","journal-title":"Nature"},{"issue":"3","key":"3282_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-013-2702-z","volume":"141","author":"O Kalous","year":"2013","unstructured":"Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerod A, Borresen-Dale AL, Slamon DJ, Finn RS (2013) AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat 141(3):397\u2013408. doi: 10.1007\/s10549-013-2702-z","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"3282_CR42","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","volume":"18","author":"M Beeram","year":"2007","unstructured":"Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18(8):1323\u20131328. doi: 10.1093\/annonc\/mdm170","journal-title":"Ann Oncol"},{"issue":"2","key":"3282_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ygyno.2005.12.019","volume":"102","author":"O Treeck","year":"2006","unstructured":"Treeck O, Wackwitz B, Haus U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102(2):292\u2013299. doi: 10.1016\/j.ygyno.2005.12.019","journal-title":"Gynecol Oncol"},{"issue":"22","key":"3282_CR44","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaeth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718\u20132724. doi: 10.1200\/JCO.2011.39.0708","journal-title":"J Clin Oncol"},{"issue":"13","key":"3282_CR45","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-13-2769","volume":"20","author":"NA O\u2019Brien","year":"2014","unstructured":"O\u2019Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ (2014) Targeting PI3K\/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20(13):3507\u20133520. doi: 10.1158\/1078-0432.CCR-13-2769","journal-title":"Clin Cancer Res"},{"key":"3282_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02359.x","author":"M Yunokawa","year":"2012","unstructured":"Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K (2012) Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci. doi: 10.1111\/j.1349-7006.2012.02359.x","journal-title":"Cancer Sci"},{"issue":"11","key":"3282_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrm1245","volume":"4","author":"M Carmena","year":"2003","unstructured":"Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4(11):842\u2013854. doi: 10.1038\/nrm1245","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3282_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/35048096","volume":"2","author":"EA Nigg","year":"2001","unstructured":"Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2(1):21\u201332. doi: 10.1038\/35048096","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"3282_CR49","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.22154","volume":"119","author":"H Yang","year":"2006","unstructured":"Yang H, He L, Kruk P, Nicosia SV, Cheng JQ (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119(10):2304\u20132312. doi: 10.1002\/ijc.22154","journal-title":"Int J Cancer"},{"issue":"54","key":"3282_CR50","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1038\/sj.onc.1209707","volume":"25","author":"X Wang","year":"2006","unstructured":"Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, Deng CX (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25(54):7148\u20137158. doi: 10.1038\/sj.onc.1209707","journal-title":"Oncogene"},{"issue":"5","key":"3282_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.7150\/ijbs.5.444","volume":"5","author":"M Taga","year":"2009","unstructured":"Taga M, Hirooka E, Ouchi T (2009) Essential roles of mTOR\/Akt pathway in Aurora-A cell transformation. Int J Biol Sci 5(5):444\u2013450","journal-title":"Int J Biol Sci"},{"issue":"7","key":"3282_CR52","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1074\/mcp.M900568-MCP200","volume":"9","author":"F Pilot-Storck","year":"2010","unstructured":"Pilot-Storck F, Chopin E, Rual JF, Baudot A, Dobrokhotov P, Robinson-Rechavi M, Brun C, Cusick ME, Hill DE, Schaeffer L, Vidal M, Goillot E (2010) Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol Cell Proteomics 9(7):1578\u20131593. doi: 10.1074\/mcp.M900568-MCP200","journal-title":"Mol Cell Proteomics"},{"issue":"18","key":"3282_CR53","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-06-2660","volume":"13","author":"L Zhang","year":"2007","unstructured":"Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O\u2019Brien-Jenkins A, Katsaros D, Butzow R, Weber BL, Coukos G (2007) Integrative genomic analysis of phosphatidylinositol 3\u2019-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13(18):5314\u20135321. doi: 10.1158\/1078-0432.CCR-06-2660","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3282_CR54","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1074\/jbc.M709300200","volume":"283","author":"X Wang","year":"2008","unstructured":"Wang X, Urvalek AM, Liu J, Zhao J (2008) Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem 283(20):13934\u201313942. doi: 10.1074\/jbc.M709300200","journal-title":"J Biol Chem"},{"issue":"27","key":"3282_CR55","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","volume":"27","author":"SL Ellard","year":"2009","unstructured":"Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. J Clin Oncol 27(27):4536\u20134541. doi: 10.1200\/JCO.2008.21.3033","journal-title":"J Clin Oncol"},{"key":"3282_CR56","unstructured":"Jerusalem G, Andre F, Chen D, Robinson D, Ozguroglu M, Lang I, White M, Toi M, Taran T, Gianni L (2013) Evaluation of everolimus in HER2+ advanced breast cancer with activated PI3K\/mTOR pathway: exploratory biomarker observations from the BOLERO-3 European Cancer Congress 2013 Abstract Book in the European Journal of Cancer 49 (Suppl 2):Abs LBA16"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3282-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3282-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:13:33Z","timestamp":1651166013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3282-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3282-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"31 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}